Literature DB >> 33613519

Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis.

Ramon V Cortez1, Luana N Moreira1, Marina Padilha2, Mariana D Bibas3, Ricardo K Toma3, Gilda Porta4, Carla R Taddei1,5.   

Abstract

Few studies reported the relation of intestinal microbiome composition and diversity in pediatric patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC). In this cross-sectional study, we selected patients younger than 19 years old from the pediatric gastroenterology and hepatology outpatient clinic of a tertiary hospital to describe the intestinal microbiome of pediatric patients with PSC associated or not to UC. Patients were divided in PSC, PSC+UC, and UC diagnosis. A stool sample was collected from each patient (n=30) and from a healthy relative/neighbor (n=23). The microbiome composition was assessed using MiSeq (Illumina) platform. Differences in microbial composition were found between PSC and PSC+UC groups. The relative abundance of Veillonella and Megasphaera genera were increased depending on patients' age at diagnosis. Veillonella was also increased in patients who were in an active status of the disease. Both genera were positively correlated to total bilirubin and gamma-glutamyl transferase. As a conclusion, the disease, the age and the disease activity status seem to influence the intestinal microbiome, highlighting the difference of intestinal microbiome profile for patients depending on age at diagnosis. We also showed an increase of Veillonella in patients with PSC and PSC+UC, and a positive correlation of dysbiosis and higher gamma-glutamyl transferase and total bilirubin in PSC+UC patients. Our findings are promising in the diagnosis, prognosis, and future therapeutic perspectives for PSC patients.
Copyright © 2021 Cortez, Moreira, Padilha, Bibas, Toma, Porta and Taddei.

Entities:  

Keywords:  16S rRNA; dysbiosis; gut microbiome; primary sclerosing cholangitis; ulcerative colitis

Mesh:

Substances:

Year:  2021        PMID: 33613519      PMCID: PMC7893080          DOI: 10.3389/fimmu.2020.598152

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  40 in total

1.  Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.

Authors:  Henry Shiau; Faith D Ihekweazu; Mansi Amin; Tatiana Fofanova; Tamir Miloh; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-10       Impact factor: 2.839

2.  Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis.

Authors:  Malte Christoph Rühlemann; Femke-Anouska Heinsen; Roman Zenouzi; Wolfgang Lieb; Andre Franke; Christoph Schramm
Journal:  Gut       Date:  2016-05-23       Impact factor: 23.059

Review 3.  Very early-onset inflammatory bowel disease: gaining insight through focused discovery.

Authors:  Christopher J Moran; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

4.  Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis.

Authors:  Einar Björnsson; Anna Cederborg; Anders Akvist; Magnus Simren; Per-Ove Stotzer; Ingvar Bjarnason
Journal:  Scand J Gastroenterol       Date:  2005-09       Impact factor: 2.423

5.  Lipopolysaccharides and beta-glucuronidase activity in choledochal bile in relation to choledocholithiasis.

Authors:  T Osnes; O Sandstad; V Skar; M Osnes
Journal:  Digestion       Date:  1997       Impact factor: 3.216

6.  Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis.

Authors:  Tobias Mueller; Claudia Beutler; Almudena Hurtado Picó; Oren Shibolet; Daniel S Pratt; Andreas Pascher; Peter Neuhaus; Bertram Wiedenmann; Thomas Berg; Daniel K Podolsky
Journal:  Liver Int       Date:  2011-09-15       Impact factor: 5.828

7.  The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.

Authors:  Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov
Journal:  Gut       Date:  2016-02-17       Impact factor: 23.059

8.  Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.

Authors:  Christian Rupp; Alexander Rössler; Taotao Zhou; Conrad Rauber; Kilian Friedrich; Andreas Wannhoff; Karl-Heinz Weiss; Peter Sauer; Peter Schirmacher; Caner Süsal; Wolfgang Stremmel; Daniel N Gotthardt
Journal:  United European Gastroenterol J       Date:  2017-06-17       Impact factor: 4.623

9.  ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.

Authors:  Arie Levine; Sibylle Koletzko; Dan Turner; Johanna C Escher; Salvatore Cucchiara; Lissy de Ridder; Kaija-Leena Kolho; Gabor Veres; Richard K Russell; Anders Paerregaard; Stephan Buderus; Mary-Louise C Greer; Jorge A Dias; Gigi Veereman-Wauters; Paolo Lionetti; Malgorzata Sladek; Javier Martin de Carpi; Annamaria Staiano; Frank M Ruemmele; David C Wilson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-06       Impact factor: 3.288

Review 10.  Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.

Authors:  Ayesha Shah; Graeme A Macdonald; Mark Morrison; Gerald Holtmann
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

View more
  2 in total

1.  Editorial: The Microbiome in Hepatobiliary and Intestinal Disease.

Authors:  Phillipp Hartmann
Journal:  Front Physiol       Date:  2022-04-13       Impact factor: 4.755

2.  Overabundance of Veillonella parvula promotes intestinal inflammation by activating macrophages via LPS-TLR4 pathway.

Authors:  Zhiyan Zhan; Wenxue Liu; Liya Pan; Yiwen Bao; Zhilong Yan; Li Hong
Journal:  Cell Death Discov       Date:  2022-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.